| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 175 | 193 | 221 | 210 | 204 | 229 | 269 | 215 | 227 | 257 | 286 | 270 | 276 | 302 | 328 | 305 | 315 | 350 | 380 | 342 | 314 | 277 | 445 | 466 | 445 | 621 | 513 | 509 | 498 | 511 | 543 | 500 | 505 | 555 | 619 | 557 | 564 | 623 | 682 | 622 |
| Expenses | 128 | 140 | 196 | 119 | 144 | 162 | 182 | 160 | 170 | 184 | 200 | 206 | 203 | 217 | 231 | 227 | 235 | 240 | 257 | 246 | 244 | 218 | 305 | 314 | 309 | 418 | 357 | 388 | 364 | 385 | 390 | 376 | 375 | 395 | 424 | 398 | 401 | 432 | 458 | 443 |
| EBITDA | 47 | 53 | 25 | 91 | 60 | 67 | 87 | 55 | 57 | 73 | 86 | 64 | 73 | 84 | 98 | 78 | 80 | 110 | 124 | 96 | 69 | 60 | 140 | 152 | 136 | 203 | 156 | 121 | 133 | 126 | 153 | 124 | 130 | 161 | 196 | 159 | 163 | 191 | 224 | 179 |
| Operating Profit % | 25 % | 26 % | 9 % | 37 % | 27 % | 27 % | 31 % | 23 % | 23 % | 26 % | 28 % | 22 % | 24 % | 26 % | 27 % | 22 % | 22 % | 28 % | 30 % | 25 % | 19 % | 18 % | 29 % | 31 % | 28 % | 31 % | 28 % | 22 % | 25 % | 23 % | 27 % | 23 % | 24 % | 27 % | 30 % | 26 % | 27 % | 28 % | 31 % | 26 % |
| Depreciation | 8 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 8 | 7 | 8 | 8 | 11 | 9 | 9 | 10 | 10 | 16 | 18 | 19 | 20 | 18 | 20 | 20 | 20 | 19 | 21 | 31 | 38 | 36 | 39 | 38 | 38 | 35 | 36 | 36 | 37 | 35 | 35 | 36 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 9 | 12 | 9 | 11 | 9 | 9 | 8 | 8 | 7 | 7 | 6 | 6 | 5 |
| Profit Before Tax | 39 | 47 | 18 | 84 | 53 | 61 | 80 | 47 | 49 | 66 | 78 | 56 | 62 | 75 | 88 | 68 | 69 | 89 | 102 | 73 | 45 | 38 | 117 | 129 | 111 | 179 | 131 | 82 | 84 | 81 | 103 | 77 | 83 | 118 | 152 | 116 | 120 | 150 | 183 | 138 |
| Tax | 10 | 16 | 11 | 23 | 18 | 21 | 27 | 16 | 17 | 22 | 27 | 19 | 22 | 26 | 31 | 22 | 22 | 30 | 21 | 19 | 13 | 10 | 30 | 33 | 26 | 46 | 34 | 23 | 21 | 23 | 30 | 23 | 26 | 34 | 42 | 34 | 34 | 42 | 52 | 40 |
| Net Profit | 29 | 31 | 7 | 61 | 35 | 40 | 53 | 31 | 32 | 44 | 51 | 36 | 40 | 50 | 57 | 46 | 47 | 59 | 81 | 55 | 33 | 28 | 87 | 96 | 85 | 134 | 96 | 58 | 62 | 58 | 72 | 54 | 57 | 84 | 111 | 82 | 86 | 108 | 131 | 98 |
| EPS in ₹ | 5.28 | 5.61 | 0.99 | 7.37 | 4.17 | 4.88 | 6.47 | 3.78 | 3.80 | 5.40 | 6.19 | 4.39 | 4.88 | 6.00 | 6.92 | 5.56 | 5.72 | 7.14 | 9.77 | 6.56 | 3.94 | 3.45 | 10.34 | 11.44 | 10.10 | 15.87 | 11.49 | 6.93 | 7.41 | 6.97 | 8.64 | 6.37 | 6.84 | 9.95 | 13.16 | 9.77 | 10.13 | 12.79 | 15.52 | 11.60 |
Dr. Lal Path Labs
2,496.20
+8.20
(0.33%)
Market Cap
20,866.17 Cr
EPS
43.05
PE Ratio
50.13
Dividend Yield
0.72 %
Industry
Healthcare Services52 Week High
3,653.95
52 Week Low
2,165.80
PB Ratio
10.44
Debt to Equity
0.19
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from20 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,008.00 | 10,345.74 | 72.42 | 568.60 | 20.11 | 120 | 35.77 | 46.88 | |
1,568.00 | 8,040.88 | 53.44 | 1,216.80 | 4.59 | 129 | 15.38 | 37.27 | |
707.00 | 3,746.64 | 42.34 | 581.30 | 8.63 | 70 | 29.25 | 41.46 | |
812.60 | 2,623.87 | 34.57 | 636.40 | 25.65 | 57 | 49.23 | 57.29 | |
1,650.00 | 1,416.15 | 29.87 | 86.70 | 25.47 | 32 | 58.82 | 41.39 | |
241.89 | 769.46 | #1 7.43 | 1,436.10 | 35.04 | 6 | -1,081.25 | 43.66 | |
350.00 | 248.47 | 21.80 | 63.00 | #1 248.07 | 7 | 133.33 | 69.90 | |
85.23 | 87.69 | 109.40 | 13.60 | -8.11 | -3 | #1 142.86 | 58.15 | |
122.55 | 85.40 | 66.60 | 36.90 | 6.34 | 1 | 0.00 | 45.73 | |
Dr. Lal Path Labs this company | 2,496.20 | #1 20,866.17 | #6 50.13 | #1 2,295.80 | #6 11.52 | #1 362 | #7 19.34 | 44.26 |
Growth Rate
Revenue Growth
11.52 %
Net Income Growth
50.27 %
Cash Flow Change
17.39 %
ROE
35.54 %
ROCE
34.91 %
EBITDA Margin (Avg.)
14.45 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 475 | 625 | 764 | 916 | 1,091 | 1,374 | 1,661 | 2,347 | 2,386 | 2,456 |
| Fixed Assets | 150 | 166 | 190 | 208 | 209 | 413 | 447 | 1,369 | 1,305 | 1,228 |
| Current Assets | 282 | 424 | 511 | 623 | 814 | 893 | 1,145 | 875 | 973 | 1,127 |
| Capital Work in Progress | 1 | 4 | 18 | 10 | 3 | 11 | 10 | 15 | 5 | 6 |
| Investments | 38 | 64 | 105 | 145 | 185 | 164 | 59 | 66 | 150 | 114 |
| Other Assets | 286 | 391 | 452 | 554 | 694 | 786 | 1,145 | 898 | 926 | 1,109 |
| Total Liabilities | 475 | 625 | 764 | 916 | 1,091 | 1,374 | 1,661 | 2,347 | 2,386 | 2,456 |
| Current Liabilities | 112 | 91 | 74 | 116 | 138 | 227 | 274 | 500 | 470 | 465 |
| Non Current Liabilities | 20 | 24 | 28 | 8 | 1 | 93 | 111 | 310 | 216 | 105 |
| Total Equity | 343 | 510 | 662 | 792 | 951 | 1,054 | 1,276 | 1,537 | 1,700 | 1,885 |
| Reserve & Surplus | 260 | 424 | 577 | 734 | 890 | 974 | 1,162 | 1,418 | 1,583 | 1,766 |
| Share Capital | 81 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 8 | -5 | 2 | 37 | 64 | 67 | 48 | 134 | -115 | 97 |
| Investing Activities | -114 | -164 | -137 | -172 | -100 | -26 | -212 | -449 | -287 | -24 |
| Operating Activities | 122 | 159 | 171 | 197 | 219 | 284 | 398 | 447 | 456 | 535 |
| Financing Activities | -1 | 0 | -32 | 13 | -55 | -190 | -139 | 136 | -283 | -414 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 55.23 % | 55.23 % | 55.23 % | 55.23 % | 55.23 % | 55.05 % | 55.05 % | 55.05 % | 55.03 % | 55.01 % | 54.61 % | 54.60 % | 54.60 % | 54.60 % | 53.92 % | 53.91 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.00 % | 1.83 % | 0.00 % | 0.00 % | 0.00 % | 26.15 % | 25.42 % | 26.82 % | 26.82 % |
| DIIs | 6.47 % | 5.61 % | 4.84 % | 5.58 % | 5.69 % | 5.30 % | 5.09 % | 6.19 % | 6.55 % | 7.33 % | 7.97 % | 8.61 % | 9.69 % | 12.71 % | 12.89 % | 13.17 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 5.70 % | 6.24 % | 6.93 % | 7.45 % | 9.03 % | 10.44 % | 8.24 % | 9.03 % | 9.50 % | 9.31 % | 8.37 % | 7.26 % | 6.47 % | 4.91 % | 4.10 % | 4.01 % |
| Others | 32.60 % | 32.92 % | 32.99 % | 31.74 % | 30.05 % | 29.22 % | 31.63 % | 27.73 % | 27.09 % | 28.35 % | 29.05 % | 29.53 % | 3.09 % | 2.35 % | 2.27 % | 2.10 % |
| No of Share Holders | 68,845 | 94,123 | 1,25,953 | 1,35,068 | 1,71,846 | 1,84,508 | 1,71,602 | 1,79,636 | 1,80,163 | 1,74,444 | 1,60,679 | 1,49,901 | 1,46,741 | 1,31,189 | 1,16,606 | 1,16,236 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 4.5 | 6 | 12 | 20 | 12 | 6 | 18 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.34 | 0.43 | 0.43 | 0.44 | 0.77 | 0.67 | 0.27 | 0.72 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Closure of Trading Window
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoUpdate On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited (A Wholly Owned Subsidiary Of The Company)9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Credit RatingMar 14, 2025
Mar 14, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Feb 08, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 07, 2025
Feb 07, 2025Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited Wholly Owned SubsidiaryFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Jan 30, 2025Integrated Filing (Financial)Jan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Jan 30, 2025Amendment In Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive InformationJan 30, 2025
Jan 30, 2025Change In Authorized Officials For The Purpose Of Determining Materiality Of Any Event Or Information Pursuant To Regulation 30 Of SEBI LODRJan 30, 2025
Jan 30, 2025In-Principle Approval Granted For Voluntary Liquidation Of Suburban Diagnostics (India) Pvt. Ltd. (Wholly Owned Subsidiary)Jan 30, 2025
Jan 30, 2025Record Date For Declaration Of 3Rd Interim Dividend For F Y 2024-25Jan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesJan 30, 2025
Jan 30, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated January 30 2025Jan 30, 2025
Jan 30, 2025Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Jan 24, 2025Board Meeting Intimation for Approval Of Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Nine Months Ended 31-12-2024 And To Consider The Proposal For Declaration Of 3RdJan 23, 2025
Jan 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Jan 08, 2025Change In Name Of Registrar And Share Transfer Agent (RTA) Of The CompanyDec 31, 2024
Dec 31, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 18, 2024
Dec 18, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 05, 2024
Dec 05, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 26, 2024
Nov 26, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 19, 2024
Nov 19, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2024
Nov 07, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 30, 2024
Oct 30, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptOct 28, 2024
Oct 28, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 24, 2024
Oct 24, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 23, 2024
Oct 23, 2024Announcement under Regulation 30 (LODR)-Investor PresentationOct 23, 2024
Oct 23, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 23, 2024
Oct 23, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateOct 23, 2024
Oct 23, 2024Record Date For Declaration Of 2Nd Interim Dividend For FY 2024-25Oct 23, 2024
Oct 23, 2024Announcement under Regulation 30 (LODR)-Dividend UpdatesOct 23, 2024
Oct 23, 2024Board Meeting Outcome for Outcome Of Board MeetingOct 23, 2024
Oct 23, 2024Results For The Period Ended September 30, 2024Oct 23, 2024
Oct 23, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 17, 2024
Oct 17, 2024Board Meeting Intimation for Approval Of The Un-Audited (Standalone & Consolidated) Financial Results For The Period Ended 30-09-2024 And To Consider The Proposal Of Declaration Of 2Nd Interim Dividend, If Any, For The Financial Year 2024-25.Oct 16, 2024
Oct 16, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 10, 2024
Oct 10, 2024Closure of Trading WindowSep 26, 2024
Sep 26, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 23, 2024
Sep 23, 2024Dissolution Of Wholly Owned Foreign SubsidiarySep 19, 2024
Sep 19, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 16, 2024
Sep 16, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Sep 16, 2024
Sep 16, 2024Technical Indicators
RSI(14)
Neutral 44.26
ATR(14)
Volatile 79.09
STOCH(9,6)
Neutral 22.42
STOCH RSI(14)
Neutral 34.16
MACD(12,26)
Bullish 7.48
ADX(14)
Weak Trend 17.07
UO(9)
Bearish 41.08
ROC(12)
Downtrend And Accelerating -4.45
WillR(14)
Neutral -64.22
About Dr. Lal Path Labs
Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371 clinical laboratories, 5,102 patient service centers, and 10,938 pickup points as of March 31, 2023. The company provides services to individual patients, hospitals, healthcare providers, and corporate customers. Its test catalog includes 481 test panels, 2763 pathology tests, and 1947 radiology and cardiology tests. Dr Lal PathLabs has expanded through acquisitions and has several domestic and international subsidiaries. The company continues to grow its network and enhance its technological capabilities to improve its diagnostic services.
Listing Date
23 Dec, 2015(9 Years,
33 days)
Website
Chairperson NameArvind Lal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
